FDA accepts Heron's painkiller re-submission; splits Blueprint Medicines' NDA for avapritinib
→ Nearly six months ago, Heron was handed an unexpected rejection by the FDA due to manufacturing concerns for HTX-011 — a long-acting non-opioid painkiller …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
